| Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. | |
| | |
MedLine Citation:
|
PMID: 20539246 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: This study assessed the efficacy, safety, and tolerability of the serotonin-norepinephrine reuptake inhibitor desvenlafaxine and the selective serotonin reuptake inhibitor escitalopram for major depressive disorder (MDD) in postmenopausal women. METHODS: In this randomized, double-blind study, postmenopausal outpatients (aged 40-70 y) with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition MDD received flexible-dose desvenlafaxine (100-200 mg/d) or escitalopram (10-20 mg/d) for 8 weeks. Acute-phase responders, that is, women with a 50% or greater reduction from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score, were eligible to continue the same double-blind treatment in the 6-month continuation phase. The primary efficacy outcomes were mean change from baseline in HAM-D17 total score (acute phase), analyzed using a mixed-effects model for repeated measures, and the proportion of women who maintained response (continuation phase), analyzed using logistic regression. RESULTS: Reductions in HAM-D17 total score at acute-phase endpoint were similar for desvenlafaxine- and escitalopram-treated women (-13.6 vs -14.3, respectively; P = 0.24). No significant difference was observed between groups at continuation-phase endpoint in the proportion of women who maintained response (desvenlafaxine, 82%; escitalopram, 80%; P = 0.70). In both phases, desvenlafaxine and escitalopram were generally safe and well tolerated. CONCLUSIONS: Among postmenopausal outpatients with MDD, there were no significant differences in the efficacy of desvenlafaxine and escitalopram based on primary efficacy analyses. The results do not support the overall hypothesis that the serotonin-norepinephrine reuptake inhibitor desvenlafaxine has an efficacy advantage for the treatment of MDD in postmenopausal women because, in this particular subgroup, desvenlafaxine failed to prove superiority over escitalopram. Safety and tolerability were comparable. |
| | |
Authors:
|
Claudio N Soares; Michael E Thase; Anita Clayton; Christine J Guico-Pabia; Kristen Focht; Qin Jiang; Susan G Kornstein; Phil Ninan; Cecelia P Kane; Lee S Cohen |
Related Documents
:
|
18511076 - Changes in bdnf serum levels in patients with major depression disorder (mdd) after 6 m... 22345126 - Vascular effects and safety of dalcetrapib in patients with or at risk of coronary hear... 3157296 - Paroxetine in the treatment of depression--a randomized comparison with amitriptyline. 16841626 - Duloxetine efficacy for major depressive disorder in male vs. female patients: data fro... 20064056 - Using an automated recruitment process to generate an unbiased study sample of multiple... 20102996 - Subjective symptoms after treatment of early lyme disease. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Menopause (New York, N.Y.) Volume: 17 ISSN: 1530-0374 ISO Abbreviation: Menopause Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-09 Completed Date: 2010-11-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9433353 Medline TA: Menopause Country: United States |
Other Details:
|
Languages: eng Pagination: 700-11 Citation Subset: IM |
Affiliation:
|
McMaster University, Hamilton, Ontario, Canada. csoares@mcmaster.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Blood Pressure Citalopram / therapeutic use* Cyclohexanols / therapeutic use* Depressive Disorder, Major / drug therapy* Double-Blind Method Female Humans Liver Function Tests Middle Aged Neurotransmitter Uptake Inhibitors / therapeutic use* Postmenopause Serotonin Uptake Inhibitors / therapeutic use* Sleep Weight Gain |
| Chemical | |
Reg. No./Substance:
|
0/Cyclohexanols; 0/Neurotransmitter Uptake Inhibitors; 0/Serotonin Uptake Inhibitors; 59729-33-8/Citalopram; 93413-62-8/O-desmethylvenlafaxine |
| Comments/Corrections | |
Comment In:
|
Menopause. 2010 Jul;17(4):672-5
[PMID:
20505543
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Synergic effect of phytoestrogens and exercise training on cardiovascular risk profile in exercise-r...
Next Document: Role of androgens in women's sexual dysfunction.